Specialty Pharma Journal Specialty, Precision & Technology
SAN FRANCISCO & BALLERUP, Denmark–(BUSINESS WIRE)–Danish dermatology specialists LEO Pharma and California rare disease pioneers PellePharm today announced a strategic development and commercialization collaboration to address unmet medical needs across various skin diseases with no approved treatments, advancing innovation and access to potential therapies for patients with life-altering conditions, such …
Tag Archives: collaborations
November, 2018
-
7 November
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines
INDIANAPOLIS and BELTSVILLE, Md., Nov. 5, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and NextCure, Inc. today announced a multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to discover novel cancer targets utilizing NextCure’s proprietary FIND-IO™ platform. Under the terms of the agreement, Lilly and NextCure will each receive options …
October, 2018
-
30 October
Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that it has entered into a non-exclusive clinical development agreement with Novartis (NYSE: NVS) to investigate one or more combination therapies for the treatment of non-alcoholic steatohepatitis (NASH). The companies will conduct both non-clinical and Phase 1 clinical studies of Pfizer’s investigational therapies, …
August, 2018
-
9 August
Ambys Medicines and Takeda Partner to Develop First-in-Class Therapies for Serious Liver Diseases
REDWOOD CITY, Calif. & OSAKA, Japan–(BUSINESS WIRE)–Ambys Medicines, a biotechnology company focused on the discovery and development of transformative therapies for people with serious liver disease, and Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) announced today that they have entered into a partnership to support the advancement of the Ambys platform …
July, 2018
-
20 July
Amgen and Cedars-Sinai Collaborate on Research, Health Service Redesign and Outcomes-Based Care
THOUSAND OAKS, Calif. and LOS ANGELES, July 19, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, cardiovascular disease, osteoporosis and migraine. The organizations intend to jointly undertake research projects in one or more of …
June, 2018
-
25 June
AbbVie and Calibr Collaborate for Development of Next Generation T-Cell Therapies
NORTH CHICAGO, Ill. and LA JOLLA, Calif., June 25, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors. This collaboration broadens AbbVie’s oncology research to access advanced precision …
-
11 June
Alexion and Complement Pharma Partner to Develop Complement Inhibitor for Neurodegenerative Disorders
NEW HAVEN, Conn., & AMSTERDAM–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Complement Pharma today announced a partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following …
December, 2017
-
15 December
Cancer Research UK and Celgene Enter Drug Discovery Collaboration
(Friday) – Cancer Research UK today announced the signing of a five-year drug-discovery collaboration between its subsidiary, Cancer Research Technology (CRT), and Celgene Corporation, to discover, develop and commercialize new anti-cancer treatments. This arrangement represents an expansion of Cancer Research Technology’s theme-based translational model that now encompasses six industry partnerships, including …
November, 2017
-
20 November
Boehringer Ingelheim Launches New Platform Offering Open Access to Many of its Best Molecules to Unlock Their Full Potential
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and …
August, 2017
-
24 August
Bioverativ and Invicro Enter Imaging Collaboration to Improve Management of Joint Health in Hemophilia Patients
WALTHAM, Mass. & BOSTON–(BUSINESS WIRE)–Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, and Invicro, LLC, a leading provider of imaging services and analysis for pharmaceutical research and development, today announced that they have formed …